The role of microbiome in rheumatoid arthritis treatment

Rahul Bodkhe, Baskar Balakrishnan, Veena Taneja

Research output: Contribution to journalReview article

Abstract

Rheumatoid arthritis (RA) is an autoimmune disorder with multifactorial etiology; both genetic and environmental factors are known to be involved in pathogenesis. Treatment with disease-modifying antirheumatic drugs (DMARDs) plays an essential role in controlling disease progression and symptoms. DMARDs have immunomodulatory properties and suppress immune response by interfering in various pro-inflammatory pathways. Recent evidence has shown that the gut microbiota directly and indirectly modulates the host immune system. RA has been associated with dysbiosis of the gut microbiota. Patients with RA treated with DMARDs show partial restoration of eubiotic gut microbiome. Hence, it is essential to understand the impact of DMARDs on the microbial composition and its consequent influences on the host immune system to identify novel therapies for RA. In this review, we discuss the importance of antirheumatic-drug-induced host microbiota modulations and possible probiotics that can generate eubiosis.

Original languageEnglish (US)
JournalTherapeutic Advances in Musculoskeletal Disease
Volume11
DOIs
StatePublished - Jan 1 2019

Fingerprint

Antirheumatic Agents
Microbiota
Rheumatoid Arthritis
Immune System
Dysbiosis
Therapeutics
Probiotics
Disease Progression
Gastrointestinal Microbiome

Keywords

  • Disease-modifying antirheumatic drugs
  • Gut microbiota
  • Immune modulation
  • Microbial modulation
  • Probiotics
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology
  • Orthopedics and Sports Medicine

Cite this

The role of microbiome in rheumatoid arthritis treatment. / Bodkhe, Rahul; Balakrishnan, Baskar; Taneja, Veena.

In: Therapeutic Advances in Musculoskeletal Disease, Vol. 11, 01.01.2019.

Research output: Contribution to journalReview article

@article{62ee9a17402b4b448029d65265e36f91,
title = "The role of microbiome in rheumatoid arthritis treatment",
abstract = "Rheumatoid arthritis (RA) is an autoimmune disorder with multifactorial etiology; both genetic and environmental factors are known to be involved in pathogenesis. Treatment with disease-modifying antirheumatic drugs (DMARDs) plays an essential role in controlling disease progression and symptoms. DMARDs have immunomodulatory properties and suppress immune response by interfering in various pro-inflammatory pathways. Recent evidence has shown that the gut microbiota directly and indirectly modulates the host immune system. RA has been associated with dysbiosis of the gut microbiota. Patients with RA treated with DMARDs show partial restoration of eubiotic gut microbiome. Hence, it is essential to understand the impact of DMARDs on the microbial composition and its consequent influences on the host immune system to identify novel therapies for RA. In this review, we discuss the importance of antirheumatic-drug-induced host microbiota modulations and possible probiotics that can generate eubiosis.",
keywords = "Disease-modifying antirheumatic drugs, Gut microbiota, Immune modulation, Microbial modulation, Probiotics, Rheumatoid arthritis",
author = "Rahul Bodkhe and Baskar Balakrishnan and Veena Taneja",
year = "2019",
month = "1",
day = "1",
doi = "10.1177/1759720X19844632",
language = "English (US)",
volume = "11",
journal = "Therapeutic Advances in Musculoskeletal Disease",
issn = "1759-720X",
publisher = "SAGE Publications Inc.",

}

TY - JOUR

T1 - The role of microbiome in rheumatoid arthritis treatment

AU - Bodkhe, Rahul

AU - Balakrishnan, Baskar

AU - Taneja, Veena

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Rheumatoid arthritis (RA) is an autoimmune disorder with multifactorial etiology; both genetic and environmental factors are known to be involved in pathogenesis. Treatment with disease-modifying antirheumatic drugs (DMARDs) plays an essential role in controlling disease progression and symptoms. DMARDs have immunomodulatory properties and suppress immune response by interfering in various pro-inflammatory pathways. Recent evidence has shown that the gut microbiota directly and indirectly modulates the host immune system. RA has been associated with dysbiosis of the gut microbiota. Patients with RA treated with DMARDs show partial restoration of eubiotic gut microbiome. Hence, it is essential to understand the impact of DMARDs on the microbial composition and its consequent influences on the host immune system to identify novel therapies for RA. In this review, we discuss the importance of antirheumatic-drug-induced host microbiota modulations and possible probiotics that can generate eubiosis.

AB - Rheumatoid arthritis (RA) is an autoimmune disorder with multifactorial etiology; both genetic and environmental factors are known to be involved in pathogenesis. Treatment with disease-modifying antirheumatic drugs (DMARDs) plays an essential role in controlling disease progression and symptoms. DMARDs have immunomodulatory properties and suppress immune response by interfering in various pro-inflammatory pathways. Recent evidence has shown that the gut microbiota directly and indirectly modulates the host immune system. RA has been associated with dysbiosis of the gut microbiota. Patients with RA treated with DMARDs show partial restoration of eubiotic gut microbiome. Hence, it is essential to understand the impact of DMARDs on the microbial composition and its consequent influences on the host immune system to identify novel therapies for RA. In this review, we discuss the importance of antirheumatic-drug-induced host microbiota modulations and possible probiotics that can generate eubiosis.

KW - Disease-modifying antirheumatic drugs

KW - Gut microbiota

KW - Immune modulation

KW - Microbial modulation

KW - Probiotics

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=85075696883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075696883&partnerID=8YFLogxK

U2 - 10.1177/1759720X19844632

DO - 10.1177/1759720X19844632

M3 - Review article

AN - SCOPUS:85075696883

VL - 11

JO - Therapeutic Advances in Musculoskeletal Disease

JF - Therapeutic Advances in Musculoskeletal Disease

SN - 1759-720X

ER -